The enzyme cytochrome P450 2C19 (CYP2C19) participates in the metabolism of a wide array of therapeutic drugs. Patients with different genotypes have been documented to have varied CYP2C19 enzyme activities and drug metabolism, resulting in significant differences in efficacy and toxic side effects of drugs.
This product is intended to provide quanlitative detection of the CYP2C19 *1, *2, *3, and *17 genes in DNA extracted from human peripheral blood samples using PCR-melting curve method. The result is expected to assist doctors to formulate a reasonable medication plan in clinical practice.